Audiologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapy.
BACKGROUND
A 48-year-old man presented to a neurologist with complaints of bilateral hearing loss and tinnitus. The patient was a member of a large family affected by neurofibromatosis type 2 and first noted hearing loss 10 years before presentation.


METHODS
Medical and neurological examination, MRI scan of the brain and spinal cord, pure-tone audiometry, NU-6 monosyllabic word test with phoneme scoring, City University of New York topic-related sentences test, noise/voice test of minimal auditory capability battery.


METHODS
Progressive neurofibromatosis-type-2-related vestibular schwannomas.


RESULTS
Annual cranial MRI and audiology, surgical resection of right vestibular schwannoma, high-power behind-the-ear hearing aid, erlotinib therapy for progressive left vestibular schwannoma.
Department of Neurology, Massachusetts General Hospital, 55 Fruit Street, Yawkey 9E, Boston, MA 02114, USA. splotkin@partners.org
Scott R
SR
Plotkin
Marybeth A
MA
Singh
Caroline C
CC
O'Donnell
Gordon J
GJ
Harris
Andrea I
AI
McClatchey
Chris
C
Halpin
D001301:Audiometry, Pure-Tone; D001309:Auditory Threshold; D019929:Cochlear Implantation / Q000379:methods*; D003131:Combined Modality Therapy; D004428:Ear Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000601:surgery*; D000069347:Erlotinib Hydrochloride; D006319:Hearing Loss, Sensorineural / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D016518:Neurofibromatosis 2 / Q000150:complications / Q000188:drug therapy* / Q000601:surgery*; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage; D011799:Quinazolines / Q000008:administration & dosage*; D016896:Treatment Outcome; D015837:Vestibular Diseases / Q000150:complications / Q000188:drug therapy / Q000601:surgery
D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride